Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Mandatum Life Insurance Company Limited to issue EUR 300 million Tier 2 notes

Press release, 30 August 2024 at 9:30 a.m. EEST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR ANY OTHER JURISDICTION OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NOTES OR THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS ANNOUNCEMENT WOULD BE UNLAWFUL. Mandatum Life Insurance Company Limited, a subsidiary of Mandatum plc, will

Resqunit AB publishes Half Year Report H1-2024

Resqunit AB (publ) ("Resqunit") August 30th, 2024, at 08.30 CET - publishes Half Year Report H1-2024Key figures (SEK) 2024 Group 2023 Group Net sales, SEK 573 046 587 982Operating profit, SEK -3 346 063 -4 558 675Earnings per share -0,24 -0,43Equity per share -0,96 0,27Outstanding shares 14 034 962 10 610 277Solidity (%) -1230% 24% 2024 compared to 2023Group revenue have been limited in both years.Operating profit amounted to -3 346 063 SEK (-4 558 675 SEK).Earnings per share -0,24

ChromoGenics Interim Report January–June 2024

Key events during Q2 2024 During the first half of 2024, ChromoGenics continued its developmental journey with a strong focus on the customer and quality, continued to take measures to lower costs, and received an order for the manufacture of ConverLight® Dynamic from one of the company’s new European partners for a non-European customer. · ChromoGenics announced that it held an Extraordinary General Meeting, at which the Meeting resolved to approve the Board’s decision according to the above on directed issues of shares and therewith related proposals. The Extraordinary General

Talkpool's interim report for the period Jan - Jun 2024

Another boring report from Talkpool with no growth and no extraordinary events but a stable business and reducing debt[][][][] Q2 (apr 1[st] – Jun 30[th]) 2024 · Net sales of EUR 3 685 thousand (comparedto EUR 3 912 thousand in Q2 2023) · EBITDA of EUR 371 thousand (EUR 432thousand in 23Q2) and EBITDA margin of 10.1%(11.0%) · EBIT of EUR 328 thousand (392) and EBITmargin of 8.9% (10.0%) · Net Earnings After Tax of EUR 150 thousand(158) and net EAT margin of 4.1% (4.0%) H1 (Jan 1[st] – Jun 30[th]) 2024 · Net sales amounted to EUR 7 659 thousand(compared

Freetrailer Group A/S presents quarterly report Q4 2023/2024

The fourth quarter of the financial year 2023/24 for Freetrailer shows a growth in revenue of 53.9%, a growth in EBITDA of 168.9% and a growth in rentals of 47.7%.High growth in revenue, operating profit and number of rentals   Revenue in the fourth quarter of the 23/24 financial year totalled DKK 31.7 million, corresponding to an increase of 53.9% compared to the same period last year.   For the full financial year, revenue totalled DKK 105.9 million. This corresponds to an increase of 41% compared to the same period last year.  Operating profit EBITDA in the fourth quarter of 23/

Biosergen publishes interim report for second quarter 2024

Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)Biosergen have treated the first patient with BSG005 ” We got the final permission to start our first patient study in Q2 and shortly after we recruited the first patient. The patient was diagnosed with Mucormycosis (black fungus) which is one of the most difficult  invasive fungal infections to treat. The patient was treated for 28 days and recovered with

ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2024

STRONG GROWTH AND PROFITABILITY DURING AN EVENTFUL QUARTER Revenues in the second quarter of 2024 amounted to SEK 507.0 (407.9) million, corresponding to 24% (24%) growth compared to the corresponding period last year. EBITDA increased to SEK 63.0 (53.7) million, and the EBITDA margin amounted to 12.4% (13.2%). During the quarter, Zinzino acquired the rights to Luxembourg-based Xelliss SA distributor database, inventory and IP assets, acquired 49% of the shares in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD and signed a letter of intent to acquire the US direct sales company

atNorth Announce Operations Director for Finland as Nordic Expansion Strategy Continues

Taina Ahti-Aalto joins atNorth to lead the operations team across new and existing facilities in Finland.Helsinki, Finland August 30[th] 2024 –  atNorth,  the leading Nordic colocation, high-performance computing, and artificial intelligence service provider, has announced the appointment of Taina Ahti-Aalto as Operations Director for Finland. Taina possesses a strong track record in leadership and business development in the critical infrastructure sector in addition to extensive experience in driving companies towards operational

Announcement of change in the total number of votes in AB SKF

Gothenburg, 30 August 2024: Due to a conversion of shares from Series A to Series B in accordance with AB SKF’s Articles of Association, the Company confirms the following. As per 30 August 2024, there are a total of 455,351,068 shares in AB SKF, out of which 29,265,933 shares are of Series A and 426,085,135 shares are of Series B. The number of votes in the Company amounts to 71,874,446.5. AB SKF does not hold any own shares. Aktiebolaget SKF      (publ) Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial

Teleste has signed EUR 53 million syndicated loan facilities agreement

Teleste CorporationStock exchange releaseAugust 30, 2024, at 9:00 a.m. EEST TELESTE HAS SIGNED EUR 53 MILLION SYNDICATED LOAN FACILITIES AGREEMENTTeleste Corporation has signed a secured syndicated EUR 53 million loan facilities agreement with its three relationship banks. The agreement includes EUR 26 million term loan and EUR 19 million revolving credit facility for refinancing the Group’s existing indebtedness, as well as commercial guarantee limits totalling EUR 8 million. The agreement has 2-year maturity with two 1-year extension options subject to lenders’ approvals. The

New number of shares and votes in Corem

As a result of Corem Property Group AB (publ)’s (“Corem”) directed issue of 28,645,832 ordinary shares of Class B, approved at an Extra General Meeting on 14 August 2024, the total number of shares and votes in Corem has changed. As of today's date, the total number of shares in Corem amounts to 1,243,489,446 shares, of which 93,730,797 are ordinary shares of Class A, 1,129,797,545 are ordinary shares of Class B, 7,545,809 are ordinary shares of Class D and 12,415,295 are preference shares. Each ordinary share of Class A entitles to one vote, while ordinary shares of Class B, ordinary

Neste's financial reporting in 2025

Neste Corporation, Stock Exchange Release, 30 August 2024 at 9 a.m. (EET)Neste Corporation will publish financial reports in 2025 as follows:Financial Statements for fiscal 2024: 13 February 2025Interim Report January-March 2025: 29 April 2025Half Year Financial Report January-June 2025: 24 July 2025Interim Report January-September 2025: 29 October 2025The Annual Report 2024 will be published on Neste's website in the week beginning on 24 February 2025. The Annual General Meeting is scheduled for Tuesday, 25 March 2025.Neste CorporationHanna MaulaVice President,

Grant of options

Faron Pharmaceuticals Ltd.   (“Faron” or “the Company”)   Grant of options   Company announcement, August 30, 2024   TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 100,000 options over new ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable

Half-year Report

30 August 2024 BISICHI PLC Interim Results for the period ended 30 June 2024 For the six months ending 30[th] June 2024: · EBITDA [1]:                     £7.35million               (2023: £1.42million)                  · Adjusted EBITDA [2]:     £6.65million                (2023: £2.17million) · Profit before tax                £5.0million                  (2023: £0.3million) · EPS (basic):                      18.33p                         (2023: Loss: 3.18p)     · The increase in group earnings in the first half of the year can be attributed to a

Unaudited Net Asset Value Update (July 2024)

Friday, 30 August 2024 KR1 plc (“KR1” or the “Company”) Unaudited Net Asset Value Update KR1 plc (KR1:ASE), a leading digital asset investment company, is pleased to announce its unaudited net asset value ("NAV") as at 31 July 2024.   Net Asset Value £127,310,747NAV per share 71.92 pGBP/USD rate 1.2852   Income from digital assets (*) £804,973 (*)   Positions (Top 10) by fair value:   Asset GBP equivalent % of portfolioCelestia ("TIA")

White Pearl Technology Group shows continuous growth in the Interim Report for the First Half of 2024

The global IT-service provider White Pearl Technology Group (WPTG) reports in the Half Year Report 2024, January to June, that the Net Revenue for H1 2024 reached SEK 139.5M, marking a 19.3% increase compared to the same period last year (SEK 116.8M in H1 2023). This growth demonstrates WPTG's ability to maintain momentum and capitalise on market opportunities. Net Profit after Tax for H1 2024 showed robust improvement, reaching SEK 17.97M, a 18.43% increase from H1 2023 (SEK 15.17M).  Highlights

Genetic Analysis AS: Publication of Half-year report 2024

OSLO, NORWAY – 30 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for H1, and april - June 2024. The Half-year report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“I am happy to see that GA continues to attract new Lab customers to use the GA-map® diagnostic system and that we are increasing our lead pipeline. Thus, our core business consisting of reagent kit sales increased 135 percent in Q2 compared to Q2

Cloudberry Clean Energy ASA | Major industry players join forces to form new contender in the Nordic power market

Oslo, Norway, 30 August 2024: Cloudberry Clean Energy ASA, Elmera Group ASA, and Småkraft AS are joining forces in balancing services and power trading through the company Kraftanmelding AS. Elmera, Småkraft and employees of Kraftanmelding are investing over NOK 20 million while Cloudberry contribute with its digital business within Captiva.Kraftanmelding is a leading provider of balancing services for run-of-river power production in Norway. Increasing amounts of intermittent power production in the Nordic region are driving the need for flexibility and active management in the energy

Biosergen have completed treatment of the first patient with BSG005

Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby announce the completion of treatment of the first patient with BSG005Invasive fungal infections represent a serious health threat, claiming 2.5 mill lives annually. There is growing resistance toward current therapy and the lack of broad-spectrum safe therapies has the WHO on high alert. It needs attention, and we need novel effective safe treatments. Biosergen is developing BSG005 designed to be safe, efficacious and broad-spectrum. We have been focusing on the starting our first patient trial in India. As

First patient dosed in Cereno Scientific’s Expanded Access Program with CS1 in rare disease Pulmonary Arterial Hypertension

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the first patient has been dosed in the Expanded Access Program (EAP) with CS1 in the rare disease Pulmonary Arterial Hypertension (PAH).“We are delighted to announce that the first patient in the EAP has been dosed. For the first time a patient, who previously completed the Phase II trial in PAH, has been provided Expanded Access to CS1. This means that the patient will receive CS1 under a prolonged protocol, a decision based

New doctoral dissertation: alternative components for safer industrial adhesives

In her dissertation, Kiilto’s Research, Development and Innovation (RDI) Director Soilikki Kotanen (M.Sc. (Tech.)) examines alternative components for the production of polyurethane materials. Her research focuses on reactive adhesives and hot-melt adhesives. The results of Kotanen’s study can be utilised in the development of industrial adhesive manufacturing processes and use of adhesives safer.Polyurethane is generally known as a component of foamed plastic, but it is also commonly used in adhesives. Typically, isocyanate is needed for the manufacture of polyurethane. However, reactive

RIGHTBRIDGE VENTURES GROUP INTERIM REPORT SECOND QUARTER 2024

1 MILLION SEK IMPROVEMENT IN EBITDA DURING THE QUARTER, THE WORK TO COMPLETE THE OV TRANSACTION CONTINUES Profit and loss, in April-June Jan-June Full yearsummary, groupSEK thousands 2024 2023 2024 2023 2023Revenue 239 1.621 577 4.151 6.691EBITDA -2.251 -3.328 -4.977 -8.795 -14.809Depreciation, -69 -781 -138 -1.822 -27.352amortization andimpairment lossesEarnings Before Interest -2.321 -4.108 -5.116 -10.618 -42.176and

Universal Music Group finds a new home in Slakthusområdet

The iconic market halls of Slakthusområdet are being transformed into unique offices and premises. At the beginning of 2026, the transformation will be completed and Hus 49 Stora Marknadshallen will become the new home of Universal Music Group. The contract with Atrium Ljungberg covers approximately 3,800 m[2] and marks yet another milestone in the development of Stockholm’s new creative district.Slakthusområdet is being developed into a new meeting place for food, culture and experiences alongside workplaces for leading creative companies in a changing and dynamic cluster. The creative

There are no items matching the current filter
There are no more items matching the current filter
Back to top